Date: 9 October 2026

ESOP Grants

Cohance Lifesciences Limited's Nomination and Remuneration Committee approved the grant of employee stock options on October 9, 2026, under two separate ESOP schemes:

ESOP 2026 Scheme Details

  • Grant of 260,194 stock options under Cohance Lifesciences Limited – Employee Stock Option Plan 2026
  • Each option convertible into one equity share of face value ₹1
  • Exercise price per option to be decided by the Board/Nomination and Remuneration Committee
  • Minimum exercise price of ₹325 for grants made within 6 months of stock exchange in-principle approval
  • For existing employees as on the effective date, grants within 10 working days of in-principle approval at fixed exercise price of ₹325
  • For grants after 6 months, exercise price not more than 20% discount to 21-day average market price
  • Vesting period: Minimum 1 year, maximum 8 years from grant date
  • Exercise period: Up to 3 years from vesting date

ESOP 2023 Scheme Details

  • Grant of 614,594 stock options under Suven Pharmaceuticals Limited – Employee Stock Option Plan 2023
  • Each option convertible into one equity share of face value ₹1
  • Fixed exercise price of ₹495 for all options
  • Vesting period: Minimum 1 year, maximum 10 years from grant date
  • Exercise period: Up to 3 years from vesting date

Total Impact

  • Combined grant of 874,788 stock options
  • Potential equity dilution of 874,788 shares upon full exercise
  • Both schemes comply with SEBI (SBEB) Regulations, 2021